|Day Low/High||224.60 / 235.77|
|52 Wk Low/High||249.17 / 388.67|
My longer-term price target is now $416.
The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #107 spot from Nielsen Holdings PLC , according to ETF Channel. Below is a chart of Biogen Inc versus Nielsen Holdings PLC plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; NLSN plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, AMOV, AMX, ARE, BIIB, BSM, DAN, DO, FUL, GIGM, JD, NGVT, OIS, WLL Downgrades: EQT, IVAC, PTNR, WP Initiations: ICCH Read on to get TheStreet Quant Ratings' detailed report:
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen's Phase 3 investigational treatment for early...
Biogen Inc. (Nasdaq: BIIB) today reported first quarter 2018 financial results, including: Total revenues of $3.
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Biogen (Nasdaq: BIIB) today announced new findings detailing the benefits that SPINRAZA ® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as...
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab).
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.
Charts are signalling more trouble ahead for the stock.
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in...
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer's and Parkinson's Therapies, an AAT-AD/PD Focus Meeting.
Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc.
TPX, WR, GOV, BIIB and SRE were all recently were downgraded by TheStreet's Quant Ratings service.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.